Abstract
Acute myeloid leukemia (AML) is characterized by the clonal expansion of immature myeloid cells, resulting in hematopoietic failure, with symptoms such as anemia and infections. Clinical outcomes are unfavorable, with an estimated overall survival inferior to 25% in five years. AML cells exhibit metabolic reprogramming that promotes dependence on oxidative phosphorylation for ATP producti…